Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04835441 · ClinicalTrials.gov registry record · Phase 2
ALPN-101 (Acazicolcept) in Systemic Lupus Erythematosus
A Phase 2 study, sponsored by Alpine Immune Sciences Inc, A Subsidiary of Vertex.
- Completed
- Registry status
- Phase 2
- Development phase
- 76
- Enrollment target
NCT04835441 is a Phase 2 study that has completed, run by Alpine Immune Sciences Inc, A Subsidiary of Vertex. The registered enrollment target is 76 participants.
The verdict
NCT04835441, a Phase 2 study, has completed, sponsored by Alpine Immune Sciences Inc, A Subsidiary of Vertex.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 76 participants
- Enrollment target
Study Summary
This is Phase 2, multinational, randomized, blinded study to evaluate the safety, tolerability, efficacy, immunogenicity, pharmacokinetics and pharmacodynamics of ALPN-101 (acazicolcept) in adults with moderate to severe active systemic lupus erythematosus (SLE)
Interventions
- DRUG Placebo
- DRUG ALPN-101
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 76 participants |
| Start Date | 2021-06-22 |
| Est. Completion | 2024-07-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04835441
The ClinicalTrials.gov registry entry for NCT04835441 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 76 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Alpine Immune Sciences Inc, A Subsidiary of Vertex, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04835441 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04835441 about?
NCT04835441 is a clinical study titled "ALPN-101 (Acazicolcept) in Systemic Lupus Erythematosus". This is Phase 2, multinational, randomized, blinded study to evaluate the safety, tolerability, efficacy, immunogenicity, pharmacokinetics and pharmacodynamics of ALPN-101 (acazicolcept) in adults with moderate to severe active systemic lupus erythematosus (SLE)
What is the current status of trial NCT04835441?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 76 participants. The study started on 2021-06-22. Estimated completion is 2024-07-09.
What interventions are being tested in trial NCT04835441?
The interventions under investigation include: Placebo (DRUG), ALPN-101 (DRUG).
Who is sponsoring clinical trial NCT04835441?
This trial is sponsored by Alpine Immune Sciences Inc, A Subsidiary of Vertex, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.